Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic
In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, discuss new data for gynecologic cancers presented at the virtual ASCO 2021 annual meeting, including novel data for single-agent immunotherapy in patients with endometrial cancer, data for novel agents targeting the folate receptor-α in ovarian cancer, and data for a novel bifunctional fusion proteins cotargeting the TGF-β receptor and PD-L1 pathways in cervical cancers.
Melissa M. Hardesty, MD, MPH
David Scott Miller, MD, FACOG, FACS
Released: June 24, 2021

In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding:

  • Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancer
  • Updated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts)
  • Final analyses from a study of mirvetuximab soravtansine plus bevacizumab in platinum-agnostic recurrent ovarian cancer
  • Results from the randomized phase III BOOST trial evaluating optimal treatment duration of bevacizumab in combination with carboplatin and paclitaxel in ovarian cancer
  • Highly anticipated results from the phase III OUTBACK trial of CRT ± adjuvant CT in women with locally advanced cervical cancer
  • A post hoc, pooled analysis, from phase I and phase II data of bintrafusp alfa, a first-in-class bifunctional fusion protein comprising a TGF-βRII (TGF-β trap) fused to a human monoclonal antibody targeting PD-L1
  • Results from a prospective multicenter phase II trial evaluating anlotinib plus sutimlimab in recurrent/advanced cervical cancers

Presenters:

David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas  

Melissa M. Hardesty, MD, MPH
Affiliate Associate Professor
OB/GYN/GYN Oncology
University of Alaska Anchorage
Gynecologic Oncologist and Managing Partner
Alaska Women’s Cancer Care
Anchorage, Alaska

Acknowledgements

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

Commentary on management challenges and incorporating novel therapies for gynecologic cancers, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Elisabeth Diver, MD Released: July 5, 2022

Podcast episode with expert insights on new data from ASCO 2022 in endometrial, ovarian, and cervical cancers, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Elisabeth Diver, MD Released: June 30, 2022

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings